Background: Sodium-glucose cotransporter-2 inhibitors (SGLT2 inhibitors) rarely cause
euglycemic diabetic ketoacidosis (euDKA) in diabetic patients. The aim was to identify …

Background and aims To study euglycemic diabetic ketoacidosis (euDKA) outcomes
associated with sodium-glucose co-transporter 2 inhibitors (SGLT2is) Methods Review of 72 …

Euglycemic diabetic ketoacidosis (EuDKA) secondary to Sodium-glucose co-transporter-2
inhibitors (SGLT2i) in type 2 diabetes mellitus (T2D) is a rare but increasingly reported …

Background Diabetic ketoacidosis (DKA) is seen relatively frequently in the emergency
department (ED). DKA is characterized by hyperglycemia, acidosis, and ketonemia, and …

SGLT-2 inhibitors have gained importance in recent years because of their cardio-protective
and reno-protective properties in diabetes. SGLT-2 inhibitors, when introduced in diabetic …

1. Background Sodiumeglucose cotransporters (SGLTs) inhibitors enhance glucose
excretion in the urine and effectively lower glucose levels in the circulation [1]. Moreover …

Background Dapagliflozin possesses the capacity to cure a wide range of diseases,
however, there are many adverse events (AEs) that have not yet been acknowledged or …

Background Sodium–glucose cotransporters (SGLTs) are present in the kidney, gut, and
heart. SGLT2 mediates kidney glucose reabsorption predominately through the proximal …

Sodium-glucose cotransporter type 2 inhibitors (SGLT2i) are oral hypoglycemic agents that
have insulin-independent glucose-lowering effects mediated by increasing the renal …

Background Sodium-Glucose Co-Transporter 2 inhibitors have been proven to have positive
effects on blood glucose control and decrease major atherosclerosis cardiac and renal …